Joel Gory

Since joining Kirkland, Joel’s representative matters have included:

• Ajax on the sale to Eli Lilly.
• KalVista on the $1.9 billion acquisition by Chiesi.
• Blackstone-backed Recognition Music Group on the acquisition of Recognition Music Group’s complete music rights portfolio by Sony Music Publishing.
• Blackstone on:
  
  • the launch of an enterprise AI services firm with Anthropic and consortium.
  • its $18.3 billion takeover offer of Hologic, together with TPG.
  • its acquisition of a majority stake in Advanced Cooling Technologies.
  • a $250 million investment in Advanced Digital Gaming.
  • its structured equity investment in Sunotec.
  • its acquisition of Arlington Industries.
  • its investment in Databricks.
  • its acquisition of the aerospace segment of TriMas, together with Tinicum.
• Amicus Therapeutics on the $4.8 billion sale to BioMarin.
• Akero Theraptutics on the on $5.2 Billion Sale to Novo Nordisk.
• Warburg Pincus on:
  • the €702 million public takeover offer for PSI Software.
  • the acquisition of Health Partners.
• Transcend Therapeutics on its sale to Otsuka.
• Eli Lilly on:
  
  • the acquisition of Kelonia Therapeutics.
  • the acquisition of Centessa.
  • the $1.925 billion acquisition of Versanis.
  • the $3.2 billion acquisition of Morphic Holding.
  • the $1.3 billion acquisition of Verve Therapeutics.
• Waters Corporation on the $39 billion combination with Becton, Dickinson’s Biosciences & Diagnostics Business.
• Walgreens Boots Alliance on the $23.7 billion acquisition by Sycamore Partners.
• The Walt Disney Company on the proposed acquisition of NFL Network and other media assets owned by the NFL.
• Centerbridge Partners on various transactions, including:
  
  • the $2 billion acquisition of MeridianLink.
  • the sale of its majority interests in APCOA.
  • the acquisition of a stake in Netwrix.
• GIC on:
  
  • the acquisition of its portfolio company Allfunds Group plc by Deutsche Börse AG.
  • the long-term strategic partnership with industrial gas maker, Messer Group.
  • the investment in Unither.
  • the investment in Synthon.
• GlaxoSmithKline plc on its $12.7 billion transaction with Pfizer Inc. to combine their consumer healthcare businesses in a new world-leading joint venture.
• Cerberus in relation to its $325 million acquisition of TE Connectivity’s Subsea Communications business (SubCom).
• TDR/Stonegate Pub Company on its £3 billion acquisition of Ei Group.
• Actis on its sale to General Atlantic.
• Akero Therapeutics on the $5.2 billion sale to Novo Nordisk.
• EQT Private Equity on its investment into IVC Evidensia.
• KKR on:
  • the acquisition of Janney Montgomery Scott.
  • the sale of DeltaValve and TapcoEnpro to SCF Partners, alongside CIRCOR.
• Macquarie Rotorcraft on the sale to Sumitomo Mitsui Finance and Leasing Company and LCI Investment.
• Clearlake Capital on its acquisition of MV Credit.
• Prince International and American Securities on the $2.1 billion acquisition of Ferro Corporation.
• Francisco Partners in $3.4 billion acquisition of Verifone Systems.
• Alteri Investors on the acquisition of CBR Fashion Group.
• Bain Capital Private Equity on $3.2 billion acquisition of Sealed Air’s Diversey Care.
• K1 Investment Management on strategic growth investment in Board Intelligence.
• TDR Capital on the acquisition of a majority stake in Asda.
• TDR Capital and I Squared on the £2.3 billion recommended cash acquisition of Aggreko.
• AppLearn International on its sale to Permira-backed Nexthink.
• Moderna on its collaboration with Immatics in relation to ground-breaking cancer vaccine development.
• Brookfield on the sale of Student Roost, the UK’s third largest purpose-built student accommodation provider, to GIC/Greystar.
• Huntsman Corporation on:
  
  • the $718 million sale of Textile Effects business to Archroma.
  • the $300 million acquisition of CVC Thermoset Specialties.
• JBT Corporation on the sale of its AeroTech business.
• Vista Equity Partners on:
  
  • the $16.5 billion acquisition of Citrix Systems, alongside Elliott Investment Management.
  • the acquisition of Farelogix, alongside Accelya.
• A confidential private equity client in relation to alleged breaches by its portfolio company of UK competition law.

Prior to joining Kirkland, Joel’s representative matters included:

Cartel and Advisory Work

• Advising a number of Hong Kong and international companies in relation to compliance with the newly-introduced Hong Kong competition law.

• Assisting Visa Europe in its defence against standalone private damages claims in UK courts.

Linklaters LLP, London

• Associate (2016–2017)

• Trainee Solicitor (2014–2016)